Yeah...it looks like you finally nailed it. That's exactly what's going to happen. There will be no pleasant surprises coming from management. There never has been in all of Moreau's tenure. He won't start now. What he's good at is dilution (see Miraculous). That goes for him and his hand picked Chairman and CFO. Moreau's picks of personnel including former CEO of Xortx as an advisor paints a pretty clear picture. Moreau thinks Xortx is doing just swell trading under 2 $ and $ not long ago since their uplist to Nasdaq. Moreau considers that good neighborly company. As in struggle together. Moreau has already telegraphed there will be a struggle ahead. Moreau says positive Phase 2 data readout is needed to approach big pharma for a handout. I don't see a Phase 2 data readout (statistically significant data readout) for any drug in the revamped pipeline until 2024 or even 2025. If there is anyone here that believes a data readout for Phase 2 will happen prior to 2024 do tell. The floor is yours.
News 
Market Data 
Discover 
